Clinical trials: Influenza Virus
Influenza, Human
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
This 2-arm study will investigate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised participants and characterize the effects of oseltamivir in immunocompromised participants on the…
- Trial name
- NCT00545532
- Testing
- oseltamivir
- Where
- 208 sites in United States, Argentina and 24 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Influenza
Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
To provide serum to the Food and Drug Administration (FDA) for use by FDA, the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) for characterization of circulating influenza strains.
- Trial name
- NCT00258817
- Testing
- Influenza Virus Vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children
To compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children who receive an intranasal placebo mist…
- Trial name
- NCT00192491
- Testing
- FluMist
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China
The main purpose of this trial is to describe the product profile in terms of immunogenicity and safety following administration of trivalent influenza vaccine (split-virion, inactivated) produced at Shenzhen (SP Shz TIV).
- Trial name
- NCT02228980
- Testing
- Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
- Where
- China
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population
The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.
- Trial name
- NCT01113580
- Testing
- CSL's 2010/2011 Formulation of Enzira® Vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)
The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.
- Trial name
- NCT00111579
- Testing
- CAIV-T, TIV
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID-19, Influenza
Performance Evaluation of the Lucira COVID-19 & Flu Test
The Lucira COVID-19\& Flu Test is a single use (disposable) RT-LAMP test kit intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B viral RNA in anterior…
- Trial name
- NCT06141824
- Testing
- Lucira COVID-19 & Flu Test
- Where
- 7 sites in United States
- Volunteers
- 1,361 people
- Sponsor
- Lucira Health Inc
Influenza
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
The objectives of this study were: To describe the safety of each dosage of high-dose quadrivalent influenza vaccine (QIV-HD) used in the study during the 28 days following each vaccination, and serious adverse events (including…
- Trial name
- QHD04 (NCT03698279)
- Testing
- High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
- Where
- 16 sites in United States, Canada
- Volunteers
- 665 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Infection
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)
This is a phase 2a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of molnupiravir (MK-4482) in healthy participants inoculated with experimental influenza virus.
- Trial name
- NCT05818124
- Testing
- Molnupiravir, Oseltamivir, Influenza A Virus
- Where
- United Kingdom
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza, Avian
Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults
This study evaluates safety, tolerability and immunogenicity of two doses of GHB04L1, a liquid formulation of the replication- deficient influenza A/Vietnam/1203/04(H5N1)-like ∆NS1 virus in healthy adults.
- Trial name
- NCT03745274
- Testing
- GHB04L1
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza
Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults
The present study is designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults aged between 19 and 61 years, previously…
- Trial name
- NCT00506350
- Testing
- Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose, Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Acute Respiratory Distress Syndrome, Influenza A
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
To investigate the safety and tolerance of a single infusion of ProTrans® in subjects with "severe" respiratory complications associated with pneumonia caused by COVID-19, Influenza A, Metapneumovirus or RSV infection.
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Influenza A, Metapneumovirus Pneumonia, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT04896853
- Testing
- ProTrans®
- Where
- Sweden
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NextCell Pharma Ab
Influenza
A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children
1. Part 1 If study subject and legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Form (In the case of study subject less than 7 years of age, written informed consent by study…
- Trial name
- NCT02541253
- Testing
- GC3110A, GCFLU Pre-filled Syringe inj.
- Where
- 12 sites in South Korea
- Volunteers
- 543 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers
This is a phase I/II, randomized, single-blind, placebo-controlled escalating double-dose study of the safety and priming potential of an intramuscular Influenza vaccine (Multimeric-001) injected to elderly volunteers.
- Trial name
- NCT01010737
- Testing
- Multimeric-001 250 mcg, Adjuvanted Multimeric-001 250mcg, Adjuvant: Montonide isa 51 VG
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza, Healthy Volunteers
Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older
Study FBP00005 is planned to be a translational Phase I, randomized, modified double-blind, active-controlled, multi-center study to be conducted in 2 stages in approximately 400 adults, 18 to 49 years of age and ≥ 60 years of…
- Trial name
- NCT06507553
- Testing
- Trivalent-Darwin influenza vaccine, Augment-Tasmania influenza vaccine, TIV-2X Darwin influenza vaccine
- Where
- 10 sites in Australia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Immunization
Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above
This is a Phase 1, parallel, randomized, active-controlled, multi-center, dose-esclation study with a Master Protocol design which will include several substudies that are developed to evaluate the safety and immunogenicity of…
- Trial name
- NCT05829356
- Testing
- H3 mRNA / LNP Vaccine, Quadrivalent recombinant influenza Vaccine (RIV4)
- Where
- 8 sites in Australia, United Kingdom
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention
One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40…
- Trial name
- NCT02015494
- Testing
- VAX2012Q
- Where
- 4 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Pandemic Influenza
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP
This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of 3 potencies (dosages) of H5N1 VLP vaccine or placebo in healthy adults 18 to 40 years of age.
- Trial name
- NCT00519389
- Testing
- H5N1 VLP Vaccine
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Novavax
Acute Respiratory Infection, Coronavirus Infection
Apple Respiratory Study
The Apple Respiratory Study, a collaboration between researchers at Apple Inc. (the "Study Sponsor" or "Sponsor") and the Seattle Flu Study team at the University of Washington (UW) (the "UW Study Team"), is a prospective…
- Conditions
- Acute Respiratory Infection, Coronavirus Infection, Influenza
- Trial name
- ARS (NCT04912180)
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Apple Inc.
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
The aim of this study is to evaluate the safety and immunogenicity of Fluzone® Quadrivalent vaccine in participants aged 6 months to < 9 years at enrollment, divided into 2 age strata (6 months to < 36 months and 3 years to < 9…
- Trial name
- NCT01946425
- Testing
- Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.